Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 320c

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of $2.75, $3.20 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $542.71 million versus the consensus estimate of $127.9 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Ross Stores (ROST) Tops Q2 EPS by 72c, Beats on Revenue
• Samsung Plans As Much As $79 Billion In Shareholder Returns - Bloomberg